Objective: To assess the relationship between chronic intake of nonsteroidal anti-inflammatory drugs (NSAID) and outcome, in particular (gastrointestinal) bleeding and to investigate whether the effect of chronic NSAID intake was similar in untreated and treated elderly hypertensives. Methods: Eligible patients (у60 years, with systolic blood pressure 160-219 mm Hg and diastolic blood pressure Ͻ95 mm Hg) were randomised to active treatment or placebo. Active treatment consisted of nitrendipine, with the possible addition of enalapril, hydrochlorothiazide, or both, titrated or combined to reduce the sitting systolic blood pressure by at least 20 mm Hg to below 150 mm Hg. Patients never taking NSAIDs (n ‫؍‬ 2882) were compared with patients on chronic NSAID intake (n ‫؍‬ 861), defined as reporting NSAID intake on at least 50% of the patient forms.
Introduction
Worldwide millions of people take acetylsalicylic acid (ASA) or other nonsteroidal anti-inflammatory drugs (NSAIDs). Their anti-inflammatory and analgesic effects are well known and the efficacy of ASA on the prevention of cardio-and cerebrovascular events has been proven. [1] [2] [3] [4] However, NSAIDs can cause gastroduodenal injury, ranging from mild dys-Results: There was a tendency towards lower mortality (relative hazard rate (95% confidence interval (CI), 0.77 (0.56-1.06)) and higher incidence of bleeding (1.13 (0.63-2.05) with chronic NSAID intake. Although there was no significant interaction between calcium-channel blocker (CCB)-based treatment and chronic NSAID intake for any of the end points, chronic NSAID intake tended to be associated with a lower incidence of bleeding on active treatment as compared to placebo (P-value of the interaction term ‫؍‬ 0.07). Conclusion: The effect of chronic NSAID intake on outcome was similar in patients on active treatment based on a dihydropyridine CCB or on placebo. However, chronic NSAID intake might have a less deleterious effect on bleeding on active treatment as compared to placebo.
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pepsia to fatal bleeding. [5] [6] [7] [8] [9] Several epidemiological studies report that intake of NSAIDs significantly increases the risk of peptic ulcer bleeding 10 and more recent data have shown that even low doses of ASA used for cardiovascular prophylaxis are not without risk of (gastrointestinal) bleeding. 1, 11 Calcium-channel blockers (CCBs) are one of the most commonly used drugs in coronary heart disease and hypertension. In 1989, over 41 million prescriptions for CCBs were dispensed in the USA. 12 However, in 1996, a randomised trial in patients undergoing cardiac valve replacement stopped prematurely, because more deaths caused by major bleeding occurred in patients taking nimodipine
Journal of Human Hypertension than among the placebo group. 13 Furthermore, in a prospective cohort study, Pahor et al 14 reported an increased risk of upper gastrointestinal bleeding associated with the use of CCBs, but several other investigators, using data from cohort 12 or casecontrol studies [15] [16] [17] [18] [19] could not confirm Pahor's results. 14 In this post-hoc analysis of the Syst-Eur data we examined the relationship between NSAID intake and outcome. Furthermore, we investigated whether there was an interaction between chronic NSAID intake and CCB-based antihypertensive treatment with regard to outcome, in particular (gastrointestinal) bleeding.
Subjects and methods
The protocol of the Syst-Eur trial is described in detail elsewhere. 20 , 21 The trial was approved by the Ethics Committees of the University of Leuven and of all participating centres and was implemented according to the principles of the declaration of Helsinki. Patients were eligible if they were at least 60 years old, had a systolic blood pressure when seated of 160-219 mm Hg with diastolic blood pressure below 95 mm Hg and a standing systolic blood pressure of at least 140 mm Hg. They also had to consent to be enrolled and to be available for longterm follow-up.
After stratification by centre, sex and previous cardiovascular complications eligible patients were randomly assigned treatment with active medication or placebo by means of a computerised random function. After randomisation, active treatment was started with the dihydropyridine CCB nitrendipine (10-40 mg per day). If necessary, nitrendipine could be combined with or replaced by enalapril (5-20 mg per day), hydrochlorothiazide (12.5-25 mg per day), or both. In the control group matching placebos were used in a similar way. By stepwise titrating and combining these study drugs, we aimed to reduce the sitting systolic blood pressure by 20 mm Hg or more to less than 150 mm Hg. Patients withdrawing from double-blind treatment remained in open follow-up.
An End-point Committee, which was unaware of the patients' treatment, validated all major end points (death, stroke, retinal haemorrhage or exudate, myocardial infarction, congestive heart failure, dissecting aneurysm, renal insufficiency). All other events (including bleedings) were checked at the coordinating office by doctors who were unaware of the patients' treatment group.
For the present analysis, patients never taking NSAIDs (n ϭ 2882) were compared with those on chronic NSAID intake (n ϭ 861), which was defined as reporting NSAID use on at least 50% of the patient forms. In patients experiencing a cardiovascular event or a bleeding, only the patient forms before the first cardiovascular event or bleeding were taken into account to determine the NSAID treatment status. Patients with a prior episode of bleeding before randomisation were not considered to be incident cases.
Database management and statistical analysis were performed with SAS software, version 6.12. The data were analysed by intention to treat with two-sided tests. Comparison of means and proportions was performed with the standard normal ztest and the 2 statistic, respectively. Relative hazard rates relating NSAID intake to various end points and the interaction between treatment and NSAID intake were studied by Cox multiple regression analysis with adjustment for randomisation group, sex, cardiovascular complications at baseline, age, systolic blood pressure at entry, residence in western Europe and smoking habits. Previous subgroup analysis had demonstrated that these variables were significant predictors of one or more end points. Table 1 shows the number of patients on ASA and/or other NSAIDs. Of the 4695 patients randomised in the Syst-Eur trial, 2882 (61.4%) never took ASA or other NSAIDs, while 861 (18.3%) patients were chronically taking ASA or other NSAIDs. In the remainder of this paper the term NSAIDs will always include ASA as well as NSAIDs other than ASA. The distribution of NSAID intake was not significantly different in the two treatment groups.
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Results
Characteristics of the patients
The baseline characteristics of patients never or chronically taking NSAIDs are shown in Table 2 . As compared to patients never taking NSAIDs, patients on chronic NSAID intake were slightly older (70.0 vs 71.0 years) and had a higher sitting SBP at entry (173.6 vs 174.5 mm Hg). At baseline, a significantly higher proportion of patients on chronic NSAID intake had a history of cardiovascular complications (38.4% vs 26.9%), stroke (3.0% vs 1.0%) or myocardial infarction (5.6% vs 2.9%). By contrast, fewer patients on chronic NSAID intake had diabetes at entry into the trial (8.5% vs 10.9%). Both groups had similar proportions of patients on previous antihypertensive medication (47.3%), anticoagulant (2.9%) or corticosteroid therapy (0.6%), current smokers (7.4%) and alcohol users (27.7%). Figure 1 shows the influence of chronic NSAID intake on end points, in both treatment groups combined. There were fewer deaths (relative hazard rate (RHR) (95% confidence interval), 0.77 (0.56-1.06)) and more bleedings (1.13 (0.63-2.05)) on chronics NSAID intake, but the confidence intervals of the relative hazard rates were wide. Thus the possibility of no effect of NSAID intake on outcome was not excluded. Table 3 shows the event rates in patients never or NSAID, nonsteroidal anti-inflammatory drug. *P Ͻ 0.05, ***P Ͻ 0.001.
Influence of NSAID intake on outcome
chronically taking NSAIDs in both treatment groups separately. Within the placebo as well as the active treatment group the rates of events were not significantly different between patients never and chronically taking NSAIDs for any of the end points.
Interaction between chronic NSAID intake and randomised treatment Table 4 shows the relative hazard rates relating chronic NSAID intake to various end points in the
Journal of Human Hypertension Figure 1 Adjusted relative hazard rates associated with chronic nonsteroidal anti-inflammatory drug (NSAID) intake as compared with never taking NSAIDs. Relative hazard rates were adjusted for randomisation group, sex, cardiovascular complications at baseline, age, systolic blood pressure, residence in eastern vs western Europe and smoking habits. The bars indicate the 95% confidence intervals. The numbers above the bars indicate the relative hazard rate relating chronic NSAID intake to the corresponding end point.
placebo and active treatment groups separately. In the placebo as well as in the active treatment group, the relative risks for fatal end points, combined fatal and non-fatal cardiovascular end points and bleeding were not significantly different between patients never and chronically taking NSAIDs. There was no significant interaction between active antihypertensive treatment and chronic NSAID use for any of the end points. However, on active treatment as compared with placebo, chronic NSAID intake tended to be associated with a lower incidence of bleeding (P value of the interaction term between NSAID intake and treatment group ϭ 0.07).
Discussion
The goal of this post-hoc analysis was to examine the effect of NSAID intake on outcome, in particular (gastrointestinal) bleeding and to investigate
Journal of Human Hypertension NSAID, nonsteroidal anti-inflammatory drug. a Relative hazard rates calculated from a regression model with treatment group, NSAID intake and the interaction term as independent covariates. Adjustments for randomisation group, sex, cardiovascular complications at baseline, age, systolic blood pressure, eastern vs western Europe and smoking habits. b Not adjusted for smoking habits (no smokers with gastrointestinal bleeding in any of the treatment groups). *P-value of the interaction term between treatment group and NSAID intake in a Cox regression model.
whether the effect of NSAIDs was similar in treated and untreated elderly hypertensive patients followed in the framework of the Syst-Eur trial.
In this paper, we present our results with all NSAIDs in one homogeneous group, although most data from the literature show that the risk of (gastrointestinal) bleeding is not the same at all doses and for all NSAIDs. 5, 9 Since this was a posthoc analysis, data on the dose of the NSAID were not always available. Furthermore, the group of patients on chronic NSAID intake was too small to analyse the data according to specific types and doses of NSAIDs. We did however run our analysis in two subgroups of patients (data not shown), ie those who chronically took ASA (700 patients) and those on chronic intake of other NSAIDs (162 patients). Although we could not run the analysis for gastrointestinal bleeding in the group of patients on chronic intake of other NSAIDs, because the number of cases was too small, the effect of chronic intake of ASA and other NSAIDs on bleeding and on other end points was similar. Therefore we decided to pool the data of these two groups.
We observed a tendency towards a lower mortality in patients on chronic NSAID intake, of whom 81% were taking ASA. This is in keeping with the results of the trials showing the protective effect of ASA on the primary 1 and secondary 2-4,23 prevention of cardio-1-4 and cerebrovascular [2] [3] [4] 23 events. Our results also showed that there was no interaction between chronic NSAID intake and CCB-based treatment with regard to outcome. However, chronic NSAID intake tended to be associated with a lower incidence of bleeding on active CCB-based antihypertensive treatment as compared to placebo. Although the point estimates of the RHRs for gastrointestinal bleeding showed a similar tendency, the very small number of cases did not permit us to draw conclusions concerning this event.
The ability of ASA and other NSAIDs to injure the gastrointestinal mucosa was recognised early after the development of these drugs and has been con-firmed extensively thereafter. 1, 5, 10, 24, 25 Many reports, most case-control studies, investigated whether use of CCBs was associated with a higher risk of (gastrointestinal) bleeding. 5, 12, [15] [16] [17] [18] [19] Several in vitro studies reported that the concurrent administration of (a low dose of) ASA or another NSAID with a CCB synergistically inhibits platelet aggregation [26] [27] [28] [29] while in vivo experiments showed inconsistent results. 30, 31 However, the question of an interaction between CCB intake and NSAID intake on the incidence of bleeding was not specifically addressed in any study. Pilotto et al 15 conducted a small casecontrol study in elderly patients. They reported that the group of patients with an upper gastrointestinal bleeding had a significantly higher percentage of NSAID (ASA and non-ASA) users than the control group (53.4% vs 19.1%), while no significant differences between the two groups were reported with regard to CCB use. Desboeuf and colleagues 19 failed to find an association between gastrointestinal haemorrhage and exposure to CCBs, whereas NSAID (ASA and non-ASA) intake was significantly related to gastrointestinal bleeding (RHR ϭ 10.9 as compared to non-NSAID users). Suissa et al 17 found that the use of CCBs was not associated with an elevated risk of (hospitalisation for) gastrointestinal bleeding, whereas the use of beta blockers was associated with a reduced risk and the use of diuretics with an increased risk. However, people on beta blockers and nonusers of antihypertensive drugs were generally less ill than the others, as reflected by their lower use of NSAIDs (excluding 'over the counter' NSAIDs such as ASA) and anti-ulcer medications. In a retrospective cohort study Smalley et al 12 found a univariate association between CCB use and bleeding from peptic ulcer. However, after controlling for important confounders (such as sex, age, use of NSAIDs, etc . . .) the difference in rates of bleeding between CCB users, beta blocker users and those who used neither drug disappeared. The result of another case-control study by Kelly et al 16 confirmed Smalley's data. Kelly et al 16 reported that the elevated unadjusted risk of upper gastrointestinal bleeding associated with CCB use was due to confounding by the concurrent use of ASA. Weil et al 18 used a large case-control study to determine risk factors for peptic ulcer bleeding other than NSAIDs (ASA and non-ASA). They reported that taking oral anticoagulants, history of previous peptic ulcer, treatment for diabetes and current smoking were all independent risk factors for peptic ulcer bleeding and that the simultaneous use of NSAIDs with one of these risk factors (except for smoking) had a multiplicative effect. They did however not find an association between CCB use and peptic ulcer bleeding. Garcia Rodriguez et al 5 examined the risk of upper gastrointestinal bleeding associated to (non-ASA) NSAID use with the risk due to CCB use in a case-control design. They confirmed the previously reported 1-1.8) ), but the authors attributed this higher risk to uncontrolled confounding.
Previously 20 we reported that the rate of bleeding was not significantly different in patients on placebo or CCB-based active treatment, regardless of NSAID intake. The present analysis showed no interaction between chronic NSAID intake and active antihypertensive treatment based on a dihydropyridine CCB with regard to the incidence of bleeding. If anything, it suggested that chronic NSAID intake might have a less deleterious effect on bleeding on CCBbased treatment as compared to placebo. Thus, our present findings do not reveal any problem that might be expected from most in vitro [26] [27] [28] [29] and some in vivo 30 platelet function studies, indicating a synergistically inhibitory effect on platelet aggregation of the concurrent use of a CCB and a NSAID, but are reassuring. However, to confirm (or refute) our data, further research is needed.
